Treatment of Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Treatment (walk-PHaSST)

Helping to find ways to improve quality of life for generations of people living with sickle cell disease and pulmonary hypertension

Treatment of Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Treatment (walk-PHaSST) examines the efficacy and safety of sildenafil to treat pulmonary hypertension, a disease significantly increasing mortality in patients with sickle cell disease. Additionally, the screening phase of walk-PHaSST will afford the opportunity to characterize the cardiovascular phenotype of 800 to 1000 patients with sickle cell disease. Study locations include nine major hospitals in the United States along with sites in the United Kingdom.

As data coordinating center for the study, Rho performs all operational, clinical, statistical, clinical data management, and regulatory support activities. Rho’s principal investigator (PI) is Nancy Yovetich (Ph.D., Research Scientist).

For more information about this research from ClinicalTrials.gov, please see below.

(This project is now complete) 

Find out more about our therapeutic expertise

Discover Rho's full range of services.